Tissue-engineered vascular structures

• US 20040044403A1
• Filed: 09/19/2003
• Published: 03/04/2004
• Est. Priority Date: 10/30/2001
• Status: Abandoned Application

• Current Assignee: Children's Medical Center Corporation
• Original Assignee: Children's Medical Center Corporation
• Inventors: Perry, Tjorvi Ellert, Kaushal, Sunjay, Bischoff, Joyce, Mayer, John E. Jr.
• Application Number:
  US10/399,092
• Publication Number:
  US 20040044403A1
• Time in Patent Office: Days
• US Class Current: 623/1.41
• CPC Class Codes: A61F 2/062 Apparatus for the production of blood vessels made from natural tissue or with layers of living cells prostheses made from natural tissue or living cells A61L27/507

Abstract

The present invention is directed to novel, less invasive and improved methods of tissue-engineering of constructs that require an endothelial surface such as blood vessels and heart valves. The constructs of the present invention possess long-term patency. The method of the present invention is particularly suited for making small diameter vessels to replace clogged or damaged coronary blood vessels, for making trileaflet heart valve conduits to replace damaged or malformed pulmonic and aortic valves, and for other vascular structures that require an endothelial surface.

Claims

1. A tissue-engineered vascular construct comprising a scaffold configured to form said construct and seeded with endothelial progenitor cells and/or SMA⁺ spindle cells capable of forming vascular tissue, said scaffold comprising a biodegradable material.

2. The tissue-engineered vascular construct of claim 1, wherein the scaffold is configured to form a tube.

3. The tissue-engineered vascular construct of claim 1, wherein the scaffold is configured to form a trileaflet heart valve.

4. A method for making a tissue-engineered vascular construct comprising the steps of:

(a) providing a substrate shaped to form the vascular construct, said substrate comprising a biodegradable material;

(b) contacting said substrate with endothelial progenitor cells and/or SMA⁺ spindle cells capable of adhering thereto and forming vascular tissue, thereby forming a primary cell-seeded construct;

(c) maintaining said primary cell-seeded construct for a first growth period in a fluid media suitable for growth of said cells and imparting stresses in the construct during said first growth phase to stimulate the physiological conditions to be encountered by the construct once implanted to form the vascular construct.

5. The method of claim 4, wherein the step of imparting stresses comprises cyclical increases in pressure and flow within said construct.

6. The method of claim 4, wherein step of imparting stresses comprises a gradual increase in shear stress.

7. The method of claim 4, wherein said biodegradable material is a polymer.

8. A tissue-engineered trileaflet heart valve produced by the method of claim 4, 5, or 6.

9. A tissue-engineered tubular construct produced by the method of claim 4, 5, or 6.

10. A tissue-engineered two-dimensional construct produced by the method of claim 4, 5, or 6.